ROS-Targeted Depression Therapy via BSA-Incubated Ceria Nanoclusters

Nano Lett. 2022 Jun 8;22(11):4519-4527. doi: 10.1021/acs.nanolett.2c01334. Epub 2022 May 18.

Abstract

Depression is one of the most fatal mental diseases, and there is currently a lack of efficient drugs for the treatment of depression. Emerging evidence has indicated oxidative stress as a key pathological feature of depression. We targeted reactive oxygen species (ROS) and synthesized CeO2@BSA nanoclusters as a novel antidepression nanodrug via a convenient, green, and highly effective bovine serum albumin (BSA) incubation strategy. CeO2@BSA has ultrasmall size (2 nm) with outstanding ROS scavenging and blood-brain barrier crossing capacity, rapid metabolism, and negligible adverse effects in vitro and in vivo. CeO2@BSA administration alleviates depressive behaviors and depression-related pathological changes of the chronic restraint stress-induced depressive model, suggesting promising therapeutic effects of CeO2@BSA for the treatment of depression. Our study proved the validity by directly using nanodrugs as antidepression drugs instead of using them as a nanocarrier, which greatly expands the application of nanomaterials in depression treatment.

Keywords: Ceria; bovine serum albumin; depression; reactive oxygen species.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Depression / drug therapy
  • Nanostructures* / therapeutic use
  • Oxidative Stress
  • Reactive Oxygen Species / metabolism
  • Serum Albumin, Bovine*

Substances

  • Reactive Oxygen Species
  • Serum Albumin, Bovine